A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy

References

• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025
   PubMed Web of Science ®Google Scholar
• Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6(4):229–239. doi:10.1016/S1470-2045(05)70094-2
   PubMed Web of Science ®Google Scholar
• Kim N, Choi SH, Chang JS, et al. Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer. Int J Gynecol Cancer. 2020;31:59–65. doi:10.1136/ijgc-2020-002031
   PubMed Web of Science ®Google Scholar
• Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci. 2008;65(20):3145–3167. doi:10.1007/s00018-008-8111-5
   PubMed Web of Science ®Google Scholar
• Biehl JK, Russell B. Introduction to stem cell therapy. J Cardiovasc Nurs. 2009;24(2):98. doi:10.1097/JCN.0b013e318197a6a5
   PubMed Web of Science ®Google Scholar
• Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20. doi:10.1186/s12929-018-0426-4
   PubMed Web of Science ®Google Scholar
• Zhang CL, Huang T, Wu BL, He WX, Liu D. Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017;8(43):75756–75766. doi:10.18632/oncotarget.20798
   PubMedGoogle Scholar
• Garibaldi C, Jereczek-Fossa BA, Marvaso G, et al. Recent advances in radiation oncology. Ecancermedicalscience. 2017;11:785. doi:10.3332/ecancer.2017.785
   PubMed Web of Science ®Google Scholar
• Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16(1):3–10. doi:10.2174/138161210789941847
   PubMed Web of Science ®Google Scholar
• Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11(3):130–135. doi:10.1016/S0962-8924(00)01906-1
   PubMed Web of Science ®Google Scholar
• Blazar BR, Lindberg FP, Ingulli E, et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med. 2001;194(4):541–549. doi:10.1084/jem.194.4.541
   PubMed Web of Science ®Google Scholar
• Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051–2054. doi:10.1126/science.288.5473.2051
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285. doi:10.1016/j.cell.2009.05.046
   PubMed Web of Science ®Google Scholar
• Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005;105(9):3577–3582. doi:10.1182/blood-2004-08-2980
   PubMed Web of Science ®Google Scholar
• Oronsky B, Carter C, Reid T, Brinkhaus F, Knox SJ. Just eat it: a review of CD47 and SIRP-alpha antagonism. Semin Oncol. 2020;47(2–3):117–124. doi:10.1053/j.seminoncol.2020.05.009
   PubMed Web of Science ®Google Scholar
• Uno S, Kinoshita Y, Azuma Y, et al. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia. Oncol Rep. 2007;17(5):1189–1194.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–299. doi:10.1016/j.cell.2009.05.045
   PubMed Web of Science ®Google Scholar
• Wang CL, Lin MJ, Hsu CY, et al. CD47 promotes cell growth and motility in epithelial ovarian cancer. Biomed Pharmacother. 2019;119:109105. doi:10.1016/j.biopha.2019.109105
   PubMed Web of Science ®Google Scholar
• Lian S, Xie R, Ye Y, et al. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine. 2019;42:281–295. doi:10.1016/j.ebiom.2019.03.018
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol. 2002;20(20):4261–4267. doi:10.1200/JCO.2002.08.674
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711–1721. doi:10.1056/NEJMoa1807315
   PubMed Web of Science ®Google Scholar
• Eladl E, Tremblay-LeMay R, Rastgoo N, et al. Role of CD47 in hematological malignancies. J Hematol Oncol. 2020;13(1):96. doi:10.1186/s13045-020-00930-1
   PubMed Web of Science ®Google Scholar
• Cioffi M, Trabulo S, Hidalgo M, et al. Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms. Clin Cancer Res. 2015;21(10):2325–2337. doi:10.1158/1078-0432.CCR-14-1399
   PubMed Web of Science ®Google Scholar
• Kaur S, Elkahloun AG, Singh SP, et al. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget. 2016;7(9):10133–10152. doi:10.18632/oncotarget.7100
   PubMedGoogle Scholar
• Liu L, Zhang L, Yang L, et al. Anti-CD47 antibody as a targeted therapeutic agent for human lung cancer and cancer stem cells. Front Immunol. 2017;8:404. doi:10.3389/fimmu.2017.00404
   PubMed Web of Science ®Google Scholar
• Dietrich A, Tanczos E, Vanscheidt W, Schopf E, Simon JC. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer. 1997;33(6):926–930. doi:10.1016/S0959-8049(96)00512-6
   PubMed Web of Science ®Google Scholar
• Thapa R, Wilson GD. The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int. 2016;2016:2087204. doi:10.1155/2016/2087204
   PubMed Web of Science ®Google Scholar
• Ranji P, Salmani Kesejini T, Saeedikhoo S, Alizadeh AM. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance. Tumour Biol. 2016;37(10):13059–13075. doi:10.1007/s13277-016-5294-5
   PubMedGoogle Scholar
• Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111–2120. doi:10.1172/JCI34401
   PubMed Web of Science ®Google Scholar
• Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V. CD133 in breast cancer cells: more than a stem cell marker. J Oncol. 2019;2019:7512632. doi:10.1155/2019/7512632
   PubMed Web of Science ®Google Scholar
• Yoshida K, Tsujimoto H, Matsumura K, et al. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 2015;4(9):1322–1333. doi:10.1002/cam4.478
   PubMed Web of Science ®Google Scholar
• Barzegar Behrooz A, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. J Drug Target. 2019;27(3):257–269. doi:10.1080/1061186X.2018.1479756
   PubMed Web of Science ®Google Scholar
• Bellomo C, Caja L, Moustakas A. Transforming growth factor beta as regulator of cancer stemness and metastasis. Br J Cancer. 2016;115(7):761–769. doi:10.1038/bjc.2016.255
   PubMed Web of Science ®Google Scholar
• Bhola NE, Balko JM, Dugger TC, et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123(3):1348–1358. doi:10.1172/JCI65416
   PubMed Web of Science ®Google Scholar
• Rabinovich I, Sebastiao APM, Lima RS, et al. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. Eur J Histochem. 2018;62(3). doi:10.4081/ejh.2018.2943.
   PubMed Web of Science ®Google Scholar
• Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7(10):11018–11032. doi:10.18632/oncotarget.6920
   PubMedGoogle Scholar
• Brewer BG, Mitchell RA, Harandi A, Eaton JW. Embryonic vaccines against cancer: an early history. Exp Mol Pathol. 2009;86(3):192–197. doi:10.1016/j.yexmp.2008.12.002
   PubMed Web of Science ®Google Scholar
• Buttle GA, Frayn A. Effect of previous injection of homologous embryonic tissue on the growth of certain transplantable mouse tumours. Nature. 1967;215(5109):1495–1497. doi:10.1038/2151495a0
   PubMed Web of Science ®Google Scholar
• Klavins JV, Mesa-Tejada R, Weiss M. Human carcinoma antigens cross reacting with anti-embryonic antibodies. Nat N Biol. 1971;234(48):153–154. doi:10.1038/newbio234153a0
   PubMedGoogle Scholar
• Yaddanapudi K, Mitchell RA, Putty K, et al. Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible? PLoS One. 2012;7(7):e42289. doi:10.1371/journal.pone.0042289
   PubMed Web of Science ®Google Scholar
• Ghosh Z, Huang M, Hu S, Wilson KD, Dey D, Wu JC. Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res. 2011;71(14):5030–5039. doi:10.1158/0008-5472.CAN-10-4402
   PubMed Web of Science ®Google Scholar
• Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499–507. doi:10.1038/ng.127
   PubMed Web of Science ®Google Scholar
• Aponte PM, Caicedo A. Stemness in cancer: stem cells, cancer stem cells, and their microenvironment. Stem Cells Int. 2017;2017:5619472. doi:10.1155/2017/5619472
   PubMed Web of Science ®Google Scholar
• Mushtaq M, Kovalevska L, Darekar S, et al. Cell stemness is maintained upon concurrent expression of RB and the mitochondrial ribosomal protein S18-2. Proc Natl Acad Sci U S A. 2020;117(27):15673–15683. doi:10.1073/pnas.1922535117
   PubMed Web of Science ®Google Scholar
• Mallon BS, Hamilton RS, Kozhich OA, et al. Comparison of the molecular profiles of human embryonic and induced pluripotent stem cells of isogenic origin. Stem Cell Res. 2014;12(2):376–386. doi:10.1016/j.scr.2013.11.010
   PubMed Web of Science ®Google Scholar
• de Almeida PE, Meyer EH, Kooreman NG, et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun. 2014;5:3903. doi:10.1038/ncomms4903
   PubMed Web of Science ®Google Scholar
• Kooreman NG, Kim Y, de Almeida PE, et al. Autologous iPSC-based vaccines elicit anti-tumor responses in vivo. Cell Stem Cell. 2018;22(4):501–13 e7. doi:10.1016/j.stem.2018.01.016
   PubMed Web of Science ®Google Scholar
• Medvedev SP, Shevchenko AI, Zakian SM. Induced pluripotent stem cells: problems and advantages when applying them in regenerative medicine. Acta Naturae. 2010;2(2):18–28. doi:10.32607/20758251-2010-2-2-18-27
   PubMed Web of Science ®Google Scholar
• Lin M, Chang AE, Wicha M, Li Q, Huang S. Development and application of cancer stem cell-targeted vaccine in cancer immunotherapy. J Vaccines Vaccin. 2017;8(6). doi:10.4172/2157-7560.1000371
   PubMedGoogle Scholar
• Ning N, Pan Q, Zheng F, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72(7):1853–1864. doi:10.1158/0008-5472.CAN-11-1400
   PubMed Web of Science ®Google Scholar
• Chu DT, Nguyen TT, Tien NLB, et al. Recent progress of stem cell therapy in cancer treatment: molecular mechanisms and potential applications. Cells. 2020;9(3):563. doi:10.3390/cells9030563
   PubMed Web of Science ®Google Scholar
• Gabka-Buszek A, Kwiatkowska-Borowczyk E, Jankowski J, Kozlowska AK, Mackiewicz A. Novel genetic melanoma vaccines based on induced pluripotent stem cells or melanosphere-derived stem-like cells display high efficacy in a murine tumor rejection model. Vaccines (Basel). 2020;8(2). doi:10.3390/vaccines8020147
   PubMed Web of Science ®Google Scholar
• Wang P, Aguirre A. New strategies and in vivo monitoring methods for stem cell-based anticancer therapies. Stem Cells Int. 2018;2018:7315218. doi:10.1155/2018/7315218
   PubMed Web of Science ®Google Scholar
• Vanden Berg-Foels WS. In situ tissue regeneration: chemoattractants for endogenous stem cell recruitment. Tissue Eng Part B Rev. 2014;20(1):28–39. doi:10.1089/ten.teb.2013.0100
   PubMed Web of Science ®Google Scholar
• Wang P, Moore A. Molecular imaging of stem cell transplantation for neurodegenerative diseases. Curr Pharm Des. 2012;18(28):4426–4440. doi:10.2174/138161212802481255
   PubMed Web of Science ®Google Scholar
• Hocking AM. The role of chemokines in mesenchymal stem cell homing to wounds. Adv Wound Care (New Rochelle). 2015;4(11):623–630. doi:10.1089/wound.2014.0579
   PubMed Web of Science ®Google Scholar
• Ren G, Roberts AI, Shi Y. Adhesion molecules: key players in Mesenchymal stem cell-mediated immunosuppression. Cell Adh Migr. 2011;5(1):20–22. doi:10.4161/cam.5.1.13491
   PubMed Web of Science ®Google Scholar
• Curfs JH, Meis JF, Hoogkamp-Korstanje JA. A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev. 1997;10(4):742–780. doi:10.1128/CMR.10.4.742
   PubMed Web of Science ®Google Scholar
• Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65(8):3307–3318. doi:10.1158/0008-5472.CAN-04-1874
   PubMed Web of Science ®Google Scholar
• Malekshah OM, Chen X, Nomani A, Sarkar S, Hatefi A. Enzyme/prodrug systems for cancer gene therapy. Curr Pharmacol Rep. 2016;2(6):299–308. doi:10.1007/s40495-016-0073-y
   PubMedGoogle Scholar
• Hasan A, Deeb G, Rahal R, et al. Mesenchymal stem cells in the treatment of traumatic brain injury. Front Neurol. 2017;8:28. doi:10.3389/fneur.2017.00028
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. doi:10.1038/s41467-018-03705-y
   PubMed Web of Science ®Google Scholar
• Layek B, Sadhukha T, Panyam J, Prabha S. Nano-engineered mesenchymal stem cells increase therapeutic efficacy of anticancer drug through true active tumor targeting. Mol Cancer Ther. 2018;17(6):1196–1206. doi:10.1158/1535-7163.MCT-17-0682
   PubMed Web of Science ®Google Scholar
• Bexell D, Gunnarsson S, Svensson A, et al. Rat multipotent mesenchymal stromal cells lack long-distance tropism to 3 different rat glioma models. Neurosurgery. 2012;70(3):731–739. doi:10.1227/NEU.0b013e318232dedd
   PubMed Web of Science ®Google Scholar
• Cheng H, Kastrup CJ, Ramanathan R, et al. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano. 2010;4(2):625–631. doi:10.1021/nn901319y
   PubMed Web of Science ®Google Scholar
• Chambers E, Mitragotri S. Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. Exp Biol Med (Maywood). 2007;232(7):958–966.
   PubMed Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond). 2016;11(6):673–692. doi:10.2217/nnm.16.5
   PubMed Web of Science ®Google Scholar
• Wang P, Yoo B, Sherman S, et al. Predictive imaging of chemotherapeutic response in a transgenic mouse model of pancreatic cancer. Int J Cancer. 2016;139(3):712–718. doi:10.1002/ijc.30098
   PubMed Web of Science ®Google Scholar
• Zhao H, Richardson R, Talebloo N, Mukherjee P, Wang P, Moore A. uMUC1-targeting magnetic resonance imaging of therapeutic response in an orthotropic mouse model of colon cancer. Mol Imaging Biol. 2019;21(5):852–860. doi:10.1007/s11307-019-01326-5
   PubMed Web of Science ®Google Scholar
• Zhao H, Hayat H, Ma X, Fan D, Wang P, Moore A. Molecular imaging and deep learning analysis of uMUC1 expression in response to chemotherapy in an orthotopic model of ovarian cancer. Sci Rep. 2020;10(1):14942. doi:10.1038/s41598-020-71890-2
   PubMed Web of Science ®Google Scholar
• Nouri FS, Wang X, Hatefi A. Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. J Control Release. 2015;200:179–187. doi:10.1016/j.jconrel.2015.01.003
   PubMed Web of Science ®Google Scholar
• Liu D, Hong Y, Li Y, et al. Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy. Theranostics. 2020;10(3):1181–1196. doi:10.7150/thno.38989
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia. 2005;21(8):779–790. doi:10.1080/02656730500271668
   PubMed Web of Science ®Google Scholar
• Calderwood SK, Theriault JR, Gong J. How is the immune response affected by hyperthermia and heat shock proteins? Int J Hyperthermia. 2005;21(8):713–716. doi:10.1080/02656730500340794
   PubMed Web of Science ®Google Scholar
• Wells J, Twamley S, Sekar A, et al. Lissajous scanning magnetic particle imaging as a multifunctional platform for magnetic hyperthermia therapy. Nanoscale. 2020;12(35):18342–18355. doi:10.1039/D0NR00604A
   PubMed Web of Science ®Google Scholar
• Khizar S, Ahmad NM, Ahmed N, et al. Aminodextran coated CoFe2O4 nanoparticles for combined magnetic resonance imaging and hyperthermia. Nanomaterials (Basel). 2020;10(11):2182. doi:10.3390/nano10112182
   PubMedGoogle Scholar
• Brennan G, Bergamino S, Pescio M, Tofail SAM, Silien C. The effects of a varied gold shell thickness on iron oxide nanoparticle cores in magnetic manipulation, T1 and T2 MRI contrasting, and magnetic hyperthermia. Nanomaterials (Basel). 2020;10(12):2424. doi:10.3390/nano10122424
   PubMedGoogle Scholar
• Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17(3):313–319. doi:10.1038/nm.2304
   PubMed Web of Science ®Google Scholar
• Borah A, Raveendran S, Rochani A, Maekawa T, Kumar DS. Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy. Oncogenesis. 2015;4:e177. doi:10.1038/oncsis.2015.35
   PubMed Web of Science ®Google Scholar
• Cheung TH, Rando TA. Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol. 2013;14(6):329–340.
   PubMed Web of Science ®Google Scholar
• Chen W, Dong J, Haiech J, Kilhoffer MC, Zeniou M. Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells Int. 2016;2016:1740936. doi:10.1155/2016/1740936
   PubMed Web of Science ®Google Scholar
• Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell. 2013;23(3):347–361. doi:10.1016/j.ccr.2013.01.026
   PubMed Web of Science ®Google Scholar
• Cho IJ, Lui PP, Obajdin J, et al. Mechanisms, hallmarks, and implications of stem cell quiescence. Stem Cell Rep. 2019;12(6):1190–1200. doi:10.1016/j.stemcr.2019.05.012
   PubMed Web of Science ®Google Scholar
• Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611–622. doi:10.1038/nrc3793
   PubMed Web of Science ®Google Scholar
• Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(13):7737–7742. doi:10.1073/pnas.1331931100
   PubMed Web of Science ®Google Scholar
• Mondala PK, Vora AA, Zhou T, et al. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell. 2021. doi:10.1016/j.stem.2020.12.017
   PubMed Web of Science ®Google Scholar
• Yaccoby S. Two states of myeloma stem cells. Clin Lymphoma Myeloma Leuk. 2018;18(1):38–43. doi:10.1016/j.clml.2017.09.020
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov. 2014;13(7):497–512. doi:10.1038/nrd4253
   PubMed Web of Science ®Google Scholar
• Mortezaee K. Hypoxia induces core-to-edge transition of progressive tumoral cells: a critical review on differential yet corroborative roles for HIF-1alpha and HIF-2alpha. Life Sci. 2020;242:117145. doi:10.1016/j.lfs.2019.117145
   PubMed Web of Science ®Google Scholar
• Najafi M, Mortezaee K, Ahadi R. Cancer stem cell (a)symmetry & plasticity: tumorigenesis and therapy relevance. Life Sci. 2019;231:116520. doi:10.1016/j.lfs.2019.05.076
   PubMed Web of Science ®Google Scholar
• Afify SM, Seno M. Conversion of stem cells to cancer stem cells: undercurrent of cancer initiation. Cancers (Basel). 2019;11(3):345. doi:10.3390/cancers11030345
   PubMed Web of Science ®Google Scholar
• Xu J, Liao K, Zhou W. Exosomes regulate the transformation of cancer cells in cancer stem cell homeostasis. Stem Cells Int. 2018;2018:4837370. doi:10.1155/2018/4837370
   PubMed Web of Science ®Google Scholar
• Li SP, Lin ZX, Jiang XY, Yu XY. Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol Sin. 2018;39(4):542–551. doi:10.1038/aps.2017.178
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715. doi:10.1016/j.cell.2008.03.027
   PubMed Web of Science ®Google Scholar
• Hollier BG, Tinnirello AA, Werden SJ, et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 2013;73(6):1981–1992. doi:10.1158/0008-5472.CAN-12-2962
   PubMed Web of Science ®Google Scholar
• Wang L, Yang G, Zhao D, et al. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p. Mol Cancer. 2019;18(1):86. doi:10.1186/s12943-019-0997-z
   PubMedGoogle Scholar
• Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 2014;15(1):65–79. doi:10.2174/1389450114666140106100909
   PubMed Web of Science ®Google Scholar
• Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011;71(15):5346–5356. doi:10.1158/0008-5472.CAN-11-0241
   PubMed Web of Science ®Google Scholar
• Kim E, Choi S, Kang B, et al. Creation of bladder assembloids mimicking tissue regeneration and cancer. Nature. 2020;588:664–669. doi:10.1038/s41586-020-3034-x
   PubMed Web of Science ®Google Scholar
• Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173(2):515–28 e17. doi:10.1016/j.cell.2018.03.017
   PubMed Web of Science ®Google Scholar
• Marton RM, Pasca SP. Organoid and assembloid technologies for investigating cellular crosstalk in human brain development and disease. Trends Cell Biol. 2020;30(2):133–143. doi:10.1016/j.tcb.2019.11.004
   PubMed Web of Science ®Google Scholar